#USA #Robbins Geller #San Diego #Class Action #Hims & Hers

Investor Alert: Hims & Hers Class Action Lawsuit

In a significant development for investors of Hims & Hers Health, Inc. (NYSE: HIMS), there is a pressing call to action for those who experienced substantial financial losses during the Class Period. The law firm Robbins Geller Rudman & Dowd LLP has declared an opportunity for these investors to lead a class action lawsuit against the company. This comes ahead of the critical deadline looming on November 2, 2026.

Background of the Case

From August 4, 2025, to July 29, 2026, investors who purchased or acquired Hims & Hers shares may qualify to sue. This class action, under the case caption Velanki v. Hims & Hers Health, Inc., alleges that the company, along with some executives, violated the Securities Exchange Act of 1934. The allegations suggest that Hims & Hers misled investors by concealing vital information regarding its business practices.

Investors are raising concerns about various claims, particularly related to the company's handling of consumer health information. Allegations state that Hims & Hers shared personal health data with third-party advertising platforms, contradicting its claims of maintaining strict consumer privacy. Moreover, it is claimed that the company engaged in deceptive practices by charging for prescriptions almost immediately after customers filled out their intake forms while misleading them about consultations with medical providers.

FTC Involvement

The situation escalated when the Federal Trade Commission (FTC) intervened. On July 29, 2026, the FTC filed a lawsuit against Hims & Hers, accusing the telehealth provider of sharing sensitive health information with third-party companies, such as Meta and Snap. This revelation caused Hims & Hers shares to plummet nearly 15%, alarming investors who may have already suffered incomprehensible losses.

The Lead Plaintiff Process

Under the Private Securities Litigation Reform Act of 1995, any investor who acquired Hims & Hers securities during the specified class period can apply to serve as the lead plaintiff in this class-action case. The selected lead plaintiff will represent the interests of all class members and is responsible for directing the course of the lawsuit. They also have the authority to select their preferred legal representation for the case. Importantly, becoming the lead plaintiff does not restrict an investor's ability to recover damages through the class action, ensuring that everyone impacted has a chance at restitution.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation. The firm has achieved significant milestones, recovering over $916 million for investors in 2025 alone, and has consistently ranked as one of the top firms in this field over the years.

Call to Action

Investors who believe they have been adversely affected by Hims & Hers practices are encouraged to act swiftly. Those wishing to become the lead plaintiff or simply learn more about their options can reach out to Robbins Geller attorneys, Ken Dolitsky or Michael Albert, by phone at 800/851-7783 or via email.

For more detailed information, please visit Robbins Geller's website. Don't miss this crucial opportunity to advocate for your rights as an investor. Act before the deadline on November 2, 2026, to ensure your voice is heard in this pivotal legal matter.